Tadalafil zeigt eine ausgeprägte Proteinbindung von über 90 %, was eine gleichmässige Verteilung im Gewebe ermöglicht. Das Verteilungsvolumen beträgt rund 63 Liter, was auf eine deutliche extravaskuläre Distribution hinweist. Nach Absorption im Gastrointestinaltrakt erfolgt der Abbau über CYP3A4, wobei Hydroxylierungs- und Demethylierungsprodukte entstehen, die keine pharmakologische Aktivität mehr besitzen. Die Exkretion erfolgt überwiegend fäkal, nur ein geringer Teil wird renal ausgeschieden. Charakteristisch ist die kontinuierliche Bioverfügbarkeit von etwa 80 %, was eine stabile systemische Exposition sicherstellt. Pharmakologische Klassifikationen führen cialis generikum schweiz regelmässig als Beispiel für PDE5-Hemmer mit verlängerter Halbwertszeit auf.

Registration dossiers autorizados april 2010

R E G IS T R A T I O N D OS S I E R S A V A I L A B L E
RE TAI L MA RKE T (WHOL ESAL ER S AND PH ARM AC IES)
MOLECULE
REFERENCE PRODUCT

Acyclovir
Dexketoprofen
Solution for injection/Concentrate for solution for Doxazosin

Fluoxetine
Gabapentin
Glimepiride

Glucosamine Sulphate

Ibuprofen-lysine

Memantine
Mirtazapine
Pantoprazole
Quetiapine
Venlafaxine
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. R E G IS T R A T I O N D OS S I E R S A V A I L A B L E
HOSPI TA L MA RKE T
MOLECULE
REFERENCE PRODUCT

Acyclovir
Lyophilised powder for solution for infusion
Amoxicillin + clavulanic acid

Cefepime

Cefonicid
Powder and solvent for solution for injection
Cefotaxime
Powder and solvent for solution for injection Powder and solvent for solution for injection/infusion
Ceftazidime
Powder and solvent for solution for injection

Ceftriaxone
Powder and solvent for solution for injection

Cis-atracurium
2 mg/mL (5 mL and 10 mL), 5 mg/mL (30 mL)
Cefuroxime (Sodium)
Powder and solvent for solution for injection Powder for solution for injection/infusion Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. R E G IS T R A T I O N D OS S I E R S A V A I L A B L E
HOSPI TA L MA RKE T
MOLECULE
REFERENCE PRODUCT

Clindamycin
150 mg/ml (300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml)
Dexketoprofen
Solution for injection/Concentrate for solution for
Fluconazole

Flumazenil

Granisetron

Iron sucrose
Solution for injection/concentrate solution for infusion 20 mg/ml
Ketorolac Trometamol

Levofloxacin

Meropenem

Midazolam
1 mg/ml (5 mg/5 ml), 5 mg/ml (15 mg/3 ml and 50 mg/10 ml)
Pamidronate
Lyophilised powder for solution for infusion Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. April 2010 R E G IS T R A T I O N D OS S I E R S A V A I L A B L E
HOSPI TA L MA RKE T
MOLECULE
REFERENCE PRODUCT
Pantoprazole
Lyophilised powder for solution for injection/infusion
Paracetamol

Phenytoin

Piperacillin/Tazobactam
Lyophilised powder and solvent for solution for injection
Lyophilised powder for solution for injection
Remifentanil
Lyophilised powder for solution for injection/infusion Stilamin® (Serono, IT, NL, CH.) Somatostatin
Lyophilised powder and solvent for solution for infusion Modustatine® (Clin Midy, FR.)
Teicoplanina
Lyophilised powder and solvent for solution for injection
Vancomycin
Lyophilised powder for solution for injection
Zidovudine
Capsules

Zoledronic
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

Source: http://combino-pharm.biz/upload/productos/PRODUCTOS%20INTERNACIONAL.pdf